Zevra Therapeutics, Inc.Zevra Therapeutics, Inc.Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪244.84 M‬USD
‪−46.05 M‬USD
‪27.46 M‬USD
‪41.54 M‬
Beta (1Y)

About Zevra Therapeutics, Inc.

Neil F. McFarlane
Employees (FY)
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Revenue to profit conversion
Debt level and coverage
Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ZVRA is 5.85 USD — it has decreased by 4.26% in the past 24 hours. Watch Zevra Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Zevra Therapeutics, Inc. stocks are traded under the ticker ZVRA.
ZVRA stock has risen by 35.10% compared to the previous week, the month change is a 17.47% rise, over the last year Zevra Therapeutics, Inc. has showed a 22.38% increase.
We've gathered analysts' opinions on Zevra Therapeutics, Inc. future price: according to them, ZVRA price has a max estimate of 24.00 USD and a min estimate of 12.00 USD. Watch ZVRA chart and read a more detailed Zevra Therapeutics, Inc. stock forecast: see what analysts think of Zevra Therapeutics, Inc. and suggest that you do with its stocks.
ZVRA reached its all-time high on Aug 14, 2015 with the price of 418.40 USD, and its all-time low was 1.94 USD and was reached on May 21, 2020. View more price dynamics on ZVRA chart.
See other stocks reaching their highest and lowest prices.
ZVRA stock is 7.83% volatile and has beta coefficient of 0.85. Track Zevra Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Zevra Therapeutics, Inc. there?
Today Zevra Therapeutics, Inc. has the market capitalization of ‪244.84 M‬, it has increased by 31.92% over the last week.
Yes, you can track Zevra Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Zevra Therapeutics, Inc. is going to release the next earnings report on Aug 13, 2024. Keep track of upcoming events with our Earnings Calendar.
ZVRA earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.47 USD resulting in a 14.29% surprise. The estimated earnings for the next quarter are −0.46 USD per share. See more details about Zevra Therapeutics, Inc. earnings.
Zevra Therapeutics, Inc. revenue for the last quarter amounts to ‪3.43 M‬ USD, despite the estimated figure of ‪3.76 M‬ USD. In the next quarter, revenue is expected to reach ‪4.42 M‬ USD.
ZVRA net income for the last quarter is ‪−16.62 M‬ USD, while the quarter before that showed ‪−15.15 M‬ USD of net income which accounts for −9.69% change. Track more Zevra Therapeutics, Inc. financial stats to get the full picture.
No, ZVRA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 13, 2024, the company has 69.00 employees. See our rating of the largest employees — is Zevra Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Zevra Therapeutics, Inc. EBITDA is ‪−54.68 M‬ USD, and current EBITDA margin is −176.97%. See more stats in Zevra Therapeutics, Inc. financial statements.
Like other stocks, ZVRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Zevra Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Zevra Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Zevra Therapeutics, Inc. stock shows the buy signal. See more of Zevra Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.